Table 2. Clinical and immunological... | American Society of Hematology

Table 2.

Clinical and immunological responses

Lptn dose level	Patient	No. injections	Local inflammatory reaction^*	Systemic immune response			Tumor response, WHO 1979		Additional therapy after relapse	Response to additional therapy	Time to relapse, d	Outcome	Survival from first injection, d
Lptn dose level	Patient	No. injections	Local inflammatory reaction^*	Ab	NK	Cytokine	Week 8	Week 24	Additional therapy after relapse	Response to additional therapy	Time to relapse, d	Outcome	Survival from first injection, d
1	1	5	+	Yes	No	NE	PD	NE	None	—	50	DOD	95
1	2	7	+	No	Yes	NE	SD	NE	Oral VP16	PR	142	DOD	730
1	3	5	+	Yes	No	NE	SD	NE	None	—	70	DOD	313
2	4	4	+	Yes	No	NE	PD	NE	Multiagent chemotherapy	PR	166	DOD	971
2	5	8	+++	Yes	No	NE	CR	PD	None	—	49	DOD	818
2	6	4	+	No	No	NE	PD	NE	None	—	53	DOD	117
3	7	2	+		Not evaluable because of rapid progression after first injection							DOD	11
3	8	2	+++		Not evaluable because of rapid progression after first injection							DOD	22
3	9	2	+		Not evaluable because of rapid progression after first injection							DOD	28
3	10	8	+++	Yes	Yes	—	SD	PD	None	—	185	DOD	257
3	11	8	++	Yes	Yes	IL-4, IL-5, IL-10	VGPR	PD	CYCHE	—	173	DOD	512
3	12	4	++		Not evaluable because of rapid progression after first injection							DOD	47
3	13	4	+	Yes	Yes	IL-4, IL-5, IL-10	PD	NE	Oral VP16	—	41	DOD	308
3	14	4	++	Yes	Yes	—	PD	NE	Oral VP16/CYCHE	MR	42	DOD	530
3	15	4	+	Yes	No	—	PD	NE	None	—	35	DOD	60
4	16	4	+	Yes	No	IL-4, IL-5, IL-10	PD	NE	Oral VP16	—	84	DOD	180
4	17	8	++	Yes	No	IL-4, IL-5, IL-10	SD	SD	CYCHE	PD	276	AWD	631+
4	18	4	0	Yes	No	—	PD	NE	None	—	106	DOD	143
4	19	5	+++	Yes	No	IL-4, IL-5, IL-10	PD	NE	None	2nd tumor	59	DOD	183
4	20	8	++	Yes	Yes	IL-4, IL-5	CR	CR	Off all therapy	—	—	NED	695+
4	21	8	+++	Yes	No	IL-4, IL-5, IL-10	SD	SD	CYCHE	SD	—	DOD	507

Lptn dose level	Patient	No. injections	Local inflammatory reaction^*	Systemic immune response			Tumor response, WHO 1979		Additional therapy after relapse	Response to additional therapy	Time to relapse, d	Outcome	Survival from first injection, d
Lptn dose level	Patient	No. injections	Local inflammatory reaction^*	Ab	NK	Cytokine	Week 8	Week 24	Additional therapy after relapse	Response to additional therapy	Time to relapse, d	Outcome	Survival from first injection, d
1	1	5	+	Yes	No	NE	PD	NE	None	—	50	DOD	95
1	2	7	+	No	Yes	NE	SD	NE	Oral VP16	PR	142	DOD	730
1	3	5	+	Yes	No	NE	SD	NE	None	—	70	DOD	313
2	4	4	+	Yes	No	NE	PD	NE	Multiagent chemotherapy	PR	166	DOD	971
2	5	8	+++	Yes	No	NE	CR	PD	None	—	49	DOD	818
2	6	4	+	No	No	NE	PD	NE	None	—	53	DOD	117
3	7	2	+		Not evaluable because of rapid progression after first injection							DOD	11
3	8	2	+++		Not evaluable because of rapid progression after first injection							DOD	22
3	9	2	+		Not evaluable because of rapid progression after first injection							DOD	28
3	10	8	+++	Yes	Yes	—	SD	PD	None	—	185	DOD	257
3	11	8	++	Yes	Yes	IL-4, IL-5, IL-10	VGPR	PD	CYCHE	—	173	DOD	512
3	12	4	++		Not evaluable because of rapid progression after first injection							DOD	47
3	13	4	+	Yes	Yes	IL-4, IL-5, IL-10	PD	NE	Oral VP16	—	41	DOD	308
3	14	4	++	Yes	Yes	—	PD	NE	Oral VP16/CYCHE	MR	42	DOD	530
3	15	4	+	Yes	No	—	PD	NE	None	—	35	DOD	60
4	16	4	+	Yes	No	IL-4, IL-5, IL-10	PD	NE	Oral VP16	—	84	DOD	180
4	17	8	++	Yes	No	IL-4, IL-5, IL-10	SD	SD	CYCHE	PD	276	AWD	631+
4	18	4	0	Yes	No	—	PD	NE	None	—	106	DOD	143
4	19	5	+++	Yes	No	IL-4, IL-5, IL-10	PD	NE	None	2nd tumor	59	DOD	183
4	20	8	++	Yes	Yes	IL-4, IL-5	CR	CR	Off all therapy	—	—	NED	695+
4	21	8	+++	Yes	No	IL-4, IL-5, IL-10	SD	SD	CYCHE	SD	—	DOD	507

Clinical status of patients was updated September 2002.

IL-4, IL-5, and IL-10 denote cytokine secretion by PBMCs restimulated by the immunizing cell line, JF.

Ab indicates antibody against the immunizing cells; VP, etoposide; CYCHE, autologous vaccine; MR, mixed response; DOD, died of disease; AWD, alive with disease; NED, no evidence of disease; NE, not evaluable; PD, progressive disease; SD, stable disease; CR, complete response; PR, partial response.

Diameter of erythema at the site of injection: 0, none; 1 cm < + ≤ 3 cm; 3 cm < ++ ≤ 8 cm; +++ > 8 cm.

View Large

This Feature Is Available To Subscribers Only